# US 12,599,350 B2 · Computed tomography based imaging of vasa vasorum density for detection and monitoring of inflammation and angiogenesis in vascular wall > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,599,350 B2 - Document ID: US12599350B2 - Status: Granted - Kind: B2 - Application number: 18/469,384 - Filed: 2023-09-18 - Published: 2024-04-11 - Granted: 2026-04-14 - Earliest claimed: 2022-10-09 - Applicants: Morteza Naghavi - Inventors: Morteza Naghavi - Web page: https://patentgrep.com/patent/US12599350B2 ## CPC - A61B 6/504: {for diagnosis of blood vessels, e.g. by angiography} - A61B 6/4417: {related to combined acquisition of different diagnostic modalities} - A61B 6/481: {involving the use of contrast agents} - A61B 6/503: {for diagnosis of the heart} - A61B 6/5217: {extracting a diagnostic or physiological parameter from medical diagnostic data} - A61B 8/0883: {for diagnosis of the heart} - A61B 8/0891: {for diagnosis of blood vessels} - A61B 8/12: in body cavities or body tracts, e.g. by using catheters - A61B 8/4416: {related to combined acquisition of different diagnostic modalities, e.g. combination of ultrasound and X-ray acquisitions} - G06T 7/0012: {Biomedical image inspection} - A61B 6/032: {Transmission computed tomography [CT]} - G06T 2207/10081: Computed x-ray tomography [CT] - G06T 2207/30101: Blood vessel; Artery; Vein; Vascular - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - G06T: IMAGE DATA PROCESSING OR GENERATION, IN GENERAL ## Abstract According to an aspect of the present invention, there is provided a method for imaging vasa vasorum density of a vessel in the body such as coronary and carotid arteries and the aorta and thereby assessing the risk of adverse health outcomes for a patient, comprising administering a contrast agent to the patient; performing a contrast-enhanced CT scan to measure Hounsfield distribution and heterogeneity related to vasa vasorum density in and around the vessel wall of a patient; analyzing the data to determine a metric related to the density of the vasa vasorum; and recommending a diagnostic and/or therapeutic next step to the patient to prevent adverse health outcomes based at least in part on the metric related to the vasa vasorum density. ## Claims ### Claim 1 A method for imaging inflammation based on quantifying vasa vasorum density in and around a coronary artery wall, comprising: performing contrast-enhanced coronary computed tomography angiography (CCTA); processing the acquired image data to measure the Hounsfield Units (HU) of voxels corresponding to contrast-enhanced microvascular structures representing vasa vasorum density within the coronary artery wall and the immediately adjacent adventitia; reporting the quantified contrast-enhanced vasa vasorum density for the coronary arteries; and recommending a diagnostic or therapeutic course of action for the patient based on the measured vasa vasorum density, wherein a higher vasa vasorum density indicates a higher risk of adverse cardiovascular outcomes. ### Claim 2 (depends on 1) The method of claim 1 further comprising a step of using a computer enabled risk calculator, wherein the risk calculator is configured to evaluate the patient based at least in part on the coronary artery calcification data, coronary plaque composition data, coronary physiology data, electrocardiogram and other clinical and laboratory diagnostic data, patient's age and sex, medical history and relevant risk factors. ### Claim 3 (depends on 2) The method of claim 2, further comprising a step of preparing for optimizing coronary revascularization procedures based at least in part on the measured density of the vasa vasorum in and around the coronary arteries of the patient. ### Claim 4 (depends on 2) The method of claim 2, wherein the measured density is used to create color coded map along the length and cross-section of a coronary artery. ### Claim 5 (depends on 4) The method of claim 4, further comprising risk assessment in patients with genetic predisposition for excessive vascular formation and angiogenesis based at least in part on the measured density of the vasa vasorum in and around the arteries of the patient. ### Claim 6 (depends on 2) The method of claim 2, wherein the data gathered from the vasa vasorum density is used to facilitate drug development for treatment of coronary heart disease and associated complications. ### Claim 7 (depends on 2) The method of claim 2, wherein the data gathered from the vasa vasorum density is used to facilitate clinical trials for studying diagnostic or therapeutic approaches to manage coronary heart disease and associated complications. ### Claim 8 (depends on 2) The method of claim 2, wherein the data gathered from the vasa vasorum density is used to facilitate clinical trials for studying diagnostic or therapeutic approaches to manage cancer and associated complications. ### Claim 9 (depends on 1) The method of claim 1, further comprising a step of assessing vasa vasorum density within the wall and the immediately adjacent adventitia of aorta, carotid, iliac, femoral, and cerebral arteries. ### Claim 10 (depends on 1) The method of claim 1, wherein artificial intelligence is used to train for quantitative measurement of vasa vasorum density and monitoring changes in vasa vasorum density and to facilitate related analysis. ### Claim 11 (depends on 1) The method of claim 1, wherein the vasa vasorum density data from the computed tomography scan is gathered within the wall and along a length of one or more of aorta, carotid artery, femoral artery, cerebral arteries, as well as left main coronary artery, left anterior descending coronary artery, left circumflex coronary artery, and right coronary artery. ### Claim 12 (depends on 11) The method of claim 11, further comprising a step of predicting the risk of the patient experiencing a sudden death or a major adverse cardiovascular event based at least in part on the measured density of the vasa vasorum in and around the arteries of the patient. ### Claim 13 (depends on 1) The method of claim 1, further comprising a step of performing a dynamic subtraction analysis of contrast enhanced CT angiography images of a segment of ana artery to measure changes in Hounsfield Units related to vasa vasorum density in and around the segment of the artery of a patient. ### Claim 14 (depends on 13) The method of claim 13, further comprising the data obtained from late enhancement of the contrast enhanced coronary CT scan in and around the wall of the coronary artery indicating leaking vasa vasorum and extravasation of the contrast agent into the wall or surrounding the coronary arteries related to coronary “blush sign”. ### Claim 15 (depends on 1) The method of claim 1, wherein the data gathered from the vasa vasorum density can improve risk assessment for patients with or at risk of aneurysms in aorta and other arteries. ### Claim 16 (depends on 1) The method of claim 1, wherein the data gathered from the vasa vasorum or angiogenesis density in and around the cancer tumors can improve risk assessment for cancer patients and monitoring angiogenesis inhibitors and other tumor suppressing agents that result in lowering the number of cancer cells therefore lowering the number of required micro-vessels to feed these cancer cells in a tumor. ### Claim 17 (depends on 1) The method of claim 1, wherein the CCTA is replaced with a virtual CCTA that results in a coronary segmentation without a contrast agent and the measured Hounsfield Units in and around the coronary wall reflects the density of blood inside the vasa vasorum.